Axitinib for the treatment of metastatic renal cell carcinoma

Future Oncology
Hiral ParekhBrian I Rini

Abstract

Renal cell carcinoma is a cancer that results from a genetic inactivation of the VHL tumor suppressor gene leading to an upregulation of VEGF. Targeted therapies against VEGF receptors have piqued substantial interest among clinicians and researchers, and these drugs are now the standard of care in the treatment of advanced renal cell carcinoma. One of these VEGF receptor inhibitors, axitinib, has been shown to be a superior second-line therapy when compared with sorafenib. Although axitinib has clinical activity and a manageable safety profile in patients with treatment-naive metastatic renal cell carcinoma, utility in the front-line setting is area of ongoing investigation. Another area of ongoing research is dose titration of axitinib to achieve the maximum clinical benefit. Interestingly, the axitinib-related side effect of hypertension has shown to be associated with more favorable clinical outcomes. This article describes the development of axitinib and discusses the current indications for clinical use in the management of metastatic renal cell carcinoma.

References

Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I Rini, Eric J Small
Jul 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S RugoGeorge Wilding
Dec 13, 2005·The New England Journal of Medicine·Herbert T Cohen, Francis J McGovern
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana D Hu-LoweSteve L Bender
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernard EscudierRonald M Bukowski
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerRobert A Figlin
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniJanice P Dutcher
Mar 31, 2010·Journal of the National Cancer Institute·Michael L MaitlandUNKNOWN Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Dr
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Brian I RiniOlivier Rixe
Jun 18, 2011·Drugs in R&D·Bernard Escudier, Martin Gore
Jul 19, 2011·Hematology/oncology Clinics of North America·Laurence AlbigesBernard Escudier
Jan 18, 2012·Expert Opinion on Drug Metabolism & Toxicology·Brian PatsonAnthony J Olszanski
Jan 17, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cora N SternbergIan D Davis
Apr 5, 2013·Journal of Clinical Pharmacology·Brian I RiniRobert J Motzer
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E HutsonRobert J Motzer
Jan 1, 2012·Biologics in Therapy·Kriti MittalBrian I Rini
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 24, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B I RiniV Grünwald
May 7, 2015·International Journal of Clinical Pharmacology and Therapeutics·James H Hertzog, Allison Radwick
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.